|Videos|July 16, 2014
Maintenance Therapy Clinical Trials for NSCLC
Advertisement
Episodes in this series
For High-Definition, Click
Maintenance therapy for the treatment of patients with non-small cell lung cancer (NSCLC) has evolved in recent years. This treatment strategy has demonstrated improvements in overall survival and progression-free survival. Both switch and continuation strategies have demonstrated value, with a number of clinical trials showing impressive findings. In this discussion, panelists discuss various clinical trials exploring maintenance therapy in NSCLC. View the video, to learn more.
Advertisement
Related to this article
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
5